Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.

Lorenzo Fornaro; Valentina Fanotto; Gianna Musettini; Mario Uccello; Lorenza Rimassa; Caterina Vivaldi; Caterina Fontanella; Francesco Leone; Riccardo Giampieri; Gerardo Rosati; Monica Lencioni; Daniele Santini; Samantha Di Donato; Gianluca Tomasello; Oronzo Brunetti; Filippo Pietrantonio; Francesca Bergamo; Mario Scartozzi; Antonio Avallone; Stefania Eufemia Lutrino; Davide Melisi; Lorenzo Antonuzzo; Antonio Pellegrino; Lorenzo Gerratana; Stefano Cordio; Enrico Vasile; Giuseppe Aprile

Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.

Lorenzo Fornaro, Valentina Fanotto, Gianna Musettini, Mario Uccello, Lorenza Rimassa, Caterina Vivaldi, Caterina Fontanella, Francesco Leone, Riccardo Giampieri, Gerardo Rosati, Monica Lencioni, Daniele Santini, Samantha Di Donato, Gianluca Tomasello, Oronzo Brunetti, Filippo Pietrantonio, Francesca Bergamo, Mario Scartozzi, Antonio Avallone, Stefania Eufemia LutrinoDavide Melisi, Lorenzo Antonuzzo, Antonio Pellegrino, Lorenzo Gerratana, Stefano Cordio, Enrico Vasile, Giuseppe Aprile

Research output: Contribution to journal › Article › peer-review

Abstract

AIM: To evaluate the impact on overall survival (OS) of gastrectomy in asymptomatic metastatic esophago-gastric cancer. PATIENTS & METHODS: Five hundred and thirteen patients were included. The role of surgery and other clinico-pathological factors was evaluated by univariate and Cox regression analyses. OS was the primary end point. RESULTS: Multivariate analysis confirmed that gastrectomy was a predictor of longer OS (p <0.001), as well as preserved performance status and benefit from first-line chemotherapy. None of the investigated clinico-pathological variables identified preferable candidates for surgery (all p > 0.05). CONCLUSION: Palliative gastrectomy might play a role in asymptomatic metastatic esophago-gastric cancer patients with good performance status who received benefit from first-line chemotherapy. Future prospective trials integrating tumor biology among inclusion criteria may help defining the optimal candidates.

Original language	English
Pages (from-to)	2265-2275
Number of pages	11
Journal	Future Oncology
Volume	13
Publication status	Published - Oct 1 2017

Keywords

chemotherapy, metastatic gastric cancer, palliative gastrectomy

Cite this

Fornaro, L., Fanotto, V., Musettini, G., Uccello, M., Rimassa, L., Vivaldi, C., Fontanella, C., Leone, F., Giampieri, R., Rosati, G., Lencioni, M., Santini, D., Donato, S. D., Tomasello, G., Brunetti, O., Pietrantonio, F., Bergamo, F., Scartozzi, M., Avallone, A., ... Aprile, G. (2017). Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. Future Oncology, 13, 2265-2275.

Fornaro, L, Fanotto, V, Musettini, G, Uccello, M, Rimassa, L, Vivaldi, C, Fontanella, C, Leone, F, Giampieri, R, Rosati, G, Lencioni, M, Santini, D, Donato, SD, Tomasello, G, Brunetti, O , Pietrantonio, F , Bergamo, F, Scartozzi, M, Avallone, A, Lutrino, SE, Melisi, D, Antonuzzo, L, Pellegrino, A, Gerratana, L, Cordio, S, Vasile, E & Aprile, G 2017, 'Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.', Future Oncology, vol. 13, pp. 2265-2275.

@article{53699b8a56f94a01837a689d1078eeaa,

title = "Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.",

abstract = "AIM: To evaluate the impact on overall survival (OS) of gastrectomy in asymptomatic metastatic esophago-gastric cancer. PATIENTS & METHODS: Five hundred and thirteen patients were included. The role of surgery and other clinico-pathological factors was evaluated by univariate and Cox regression analyses. OS was the primary end point. RESULTS: Multivariate analysis confirmed that gastrectomy was a predictor of longer OS (p <0.001), as well as preserved performance status and benefit from first-line chemotherapy. None of the investigated clinico-pathological variables identified preferable candidates for surgery (all p > 0.05). CONCLUSION: Palliative gastrectomy might play a role in asymptomatic metastatic esophago-gastric cancer patients with good performance status who received benefit from first-line chemotherapy. Future prospective trials integrating tumor biology among inclusion criteria may help defining the optimal candidates.",

keywords = "chemotherapy, metastatic gastric cancer, palliative gastrectomy",

author = "Lorenzo Fornaro and Valentina Fanotto and Gianna Musettini and Mario Uccello and Lorenza Rimassa and Caterina Vivaldi and Caterina Fontanella and Francesco Leone and Riccardo Giampieri and Gerardo Rosati and Monica Lencioni and Daniele Santini and Donato, {Samantha Di} and Gianluca Tomasello and Oronzo Brunetti and Filippo Pietrantonio and Francesca Bergamo and Mario Scartozzi and Antonio Avallone and Lutrino, {Stefania Eufemia} and Davide Melisi and Lorenzo Antonuzzo and Antonio Pellegrino and Lorenzo Gerratana and Stefano Cordio and Enrico Vasile and Giuseppe Aprile",

year = "2017",

month = oct,

day = "1",

language = "English",

volume = "13",

pages = "2265--2275",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

}

TY - JOUR

T1 - Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.

AU - Fornaro, Lorenzo

AU - Fanotto, Valentina

AU - Musettini, Gianna

AU - Uccello, Mario

AU - Rimassa, Lorenza

AU - Vivaldi, Caterina

AU - Fontanella, Caterina

AU - Leone, Francesco

AU - Giampieri, Riccardo

AU - Rosati, Gerardo

AU - Lencioni, Monica

AU - Santini, Daniele

AU - Donato, Samantha Di

AU - Tomasello, Gianluca

AU - Brunetti, Oronzo

AU - Pietrantonio, Filippo

AU - Bergamo, Francesca

AU - Scartozzi, Mario

AU - Avallone, Antonio

AU - Lutrino, Stefania Eufemia

AU - Melisi, Davide

AU - Antonuzzo, Lorenzo

AU - Pellegrino, Antonio

AU - Gerratana, Lorenzo

AU - Cordio, Stefano

AU - Vasile, Enrico

AU - Aprile, Giuseppe

PY - 2017/10/1

Y1 - 2017/10/1

N2 - AIM: To evaluate the impact on overall survival (OS) of gastrectomy in asymptomatic metastatic esophago-gastric cancer. PATIENTS & METHODS: Five hundred and thirteen patients were included. The role of surgery and other clinico-pathological factors was evaluated by univariate and Cox regression analyses. OS was the primary end point. RESULTS: Multivariate analysis confirmed that gastrectomy was a predictor of longer OS (p <0.001), as well as preserved performance status and benefit from first-line chemotherapy. None of the investigated clinico-pathological variables identified preferable candidates for surgery (all p > 0.05). CONCLUSION: Palliative gastrectomy might play a role in asymptomatic metastatic esophago-gastric cancer patients with good performance status who received benefit from first-line chemotherapy. Future prospective trials integrating tumor biology among inclusion criteria may help defining the optimal candidates.

AB - AIM: To evaluate the impact on overall survival (OS) of gastrectomy in asymptomatic metastatic esophago-gastric cancer. PATIENTS & METHODS: Five hundred and thirteen patients were included. The role of surgery and other clinico-pathological factors was evaluated by univariate and Cox regression analyses. OS was the primary end point. RESULTS: Multivariate analysis confirmed that gastrectomy was a predictor of longer OS (p <0.001), as well as preserved performance status and benefit from first-line chemotherapy. None of the investigated clinico-pathological variables identified preferable candidates for surgery (all p > 0.05). CONCLUSION: Palliative gastrectomy might play a role in asymptomatic metastatic esophago-gastric cancer patients with good performance status who received benefit from first-line chemotherapy. Future prospective trials integrating tumor biology among inclusion criteria may help defining the optimal candidates.

KW - chemotherapy, metastatic gastric cancer, palliative gastrectomy

M3 - Article

VL - 13

SP - 2265

EP - 2275

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

ER -

Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.

Abstract

Keywords

Fingerprint

Cite this